Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGiNAUT Phase IIb study of AZD8965 in idiopathic pulmonary fibrosis
2025-525016-41-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing AZD8965 with Placebo to AZD8965 (2 arms). Primary endpoint: Change from baseline in forced vital capacity. Planned start Sep 2026; status: authorised.
02
Drugs
AZD8965
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-525016-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525016-41-00.